• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Complement activation in the disease course of COVID-19 and its effects on clinical outcomes

tetano

Editor, Senior Moderator
J Infect Dis


. 2020 Oct 10;jiaa646.
doi: 10.1093/infdis/jiaa646. Online ahead of print.
Complement activation in the disease course of COVID-19 and its effects on clinical outcomes


Aline H de Nooijer[SUP] 1 [/SUP], Inge Grondman[SUP] 1 [/SUP], Nico A F Janssen[SUP] 1 [/SUP], Mihai G Netea[SUP] 1 2 [/SUP], Loek Willems[SUP] 3 [/SUP], Frank L van de Veerdonk[SUP] 1 [/SUP], Evangelos J Giamarellos-Bourboulis[SUP] 4 [/SUP], Erik J M Toonen[SUP] 3 [/SUP], Leo A B Joosten[SUP] 1 5 [/SUP]



Affiliations

Abstract

Background: Excessive activation of immune responses in coronavirus disease 2019 (COVID-19) is considered to be related to disease severity, complications and mortality. The complement system is an important component of innate immunity and can stimulate inflammation, but its role in COVID-19 is unknown.
Methods: A prospective, longitudinal, single center study was performed in hospitalized COVID-19 patients. Plasma concentrations of complement factors C3a, C3c, and terminal complement complex (TCC) were assessed at baseline and during hospital admission. In parallel, routine laboratory and clinical parameters were collected from medical files and analyzed.
Results: Complement factors C3a, C3c and TCC were significantly increased in plasma of COVID-19 patients compared to healthy controls (p<0.05). These complement factors were especially elevated in ICU patients during the entire disease course (p<0.005 for C3a and TCC). More intense complement activation was observed in patients that deceased and in patients with thromboembolic events.
Conclusions: COVID-19 patients demonstrate activation of the complement system, which is related to disease severity. This pathway may be involved in the dysregulated pro-inflammatory response associated with increased mortality and thromboembolic complications. Components of the complement system might have potential as prognostic markers for disease severity and as therapeutic targets in COVID-19.

Keywords: ARDS; COVID-19; Coagulation; Complement; Inflammation; SARS-CoV-2.
 
Back
Top Bottom